Roivant Sciences Ltd
ROIV25.820USD
+4.680+22.14%
終値 02/06, 16:00（ET）15分遅れの株価
17.81B時価総額
損失額直近12ヶ月PER
詳細情報 Roivant Sciences Ltd 企業名
Roivant Sciences Ltd. is a biopharmaceutical company focused on improving the lives of patients by accelerating the development and commercialization of medicines that matter. The Company’s pipeline includes brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis, non-infectious uveitis and cutaneous sarcoidosis; IMVT-1402 and batoclimab, fully human monoclonal antibodies targeting FcRn in development across several IgG-mediated autoimmune indications; and mosliciguat, an inhaled sGC activator in development for pulmonary hypertension associated with interstitial lung disease. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business.
Roivant Sciences Ltdの企業情報
企業コードROIV
会社名Roivant Sciences Ltd
上場日Dec 03, 2020
最高経営責任者「CEO」Venker (Eric)
従業員数750
証券種類Ordinary Share
決算期末Dec 03
本社所在地7Th Floor, 50 Broadway
都市LONDON
証券取引所NASDAQ OMX - NASDAQ BASIC
国United Kingdom
郵便番号SW1H 0DB
電話番号4412955950
ウェブサイトhttp://roivant.com/
企業コードROIV
上場日Dec 03, 2020
最高経営責任者「CEO」Venker (Eric)
Roivant Sciences Ltdの経営陣
会社名
会社名/ポジション
ポジション
株式保有
変動額
Dr. Frank M. Torti, M.D.
Dr. Frank M. Torti, M.D.
President and Vant Chairman
President and Vant Chairman
13.74M
--
Dr. Keith S. Manchester, M.D.
Dr. Keith S. Manchester, M.D.
Independent Director
Independent Director
1.93M
+14524.00%
Dr. Eric Venker, M.D.
Dr. Eric Venker, M.D.
President and Immunovant Chief Executive Officer
President and Immunovant Chief Executive Officer
1.50M
--
Ms. Jennifer Humes
Ms. Jennifer Humes
Chief Accounting Officer
Chief Accounting Officer
112.25K
+112255.00%
Mr. Ilan Oren
Mr. Ilan Oren
Independent Chairman of the Board
Independent Chairman of the Board
100.84K
+1040.00%
Mr. James C. (Jim) Momtazee
Mr. James C. (Jim) Momtazee
Independent Director
Independent Director
92.62K
+487.00%
Mr. Matthew Gline
Mr. Matthew Gline
Chief Executive Officer, Director
Chief Executive Officer, Director
82.26K
--
Ms. Melissa B. Epperly
Ms. Melissa B. Epperly
Independent Director
Independent Director
41.26K
+761.00%
Mr. Richard Pulik
Mr. Richard Pulik
Chief Financial Officer
Chief Financial Officer
37.59K
-148860.00%
Dr. Mayukh Sukhatme, M.D.
Dr. Mayukh Sukhatme, M.D.
President, Chief Investment Officer, Director
President, Chief Investment Officer, Director
--
-20494245.00%
詳細を見る
会社名
会社名/ポジション
ポジション
株式保有
変動額
Dr. Frank M. Torti, M.D.
Dr. Frank M. Torti, M.D.
President and Vant Chairman
President and Vant Chairman
13.74M
--
Dr. Keith S. Manchester, M.D.
Dr. Keith S. Manchester, M.D.
Independent Director
Independent Director
1.93M
+14524.00%
Dr. Eric Venker, M.D.
Dr. Eric Venker, M.D.
President and Immunovant Chief Executive Officer
President and Immunovant Chief Executive Officer
1.50M
--
Ms. Jennifer Humes
Ms. Jennifer Humes
Chief Accounting Officer
Chief Accounting Officer
112.25K
+112255.00%
Mr. Ilan Oren
Mr. Ilan Oren
Independent Chairman of the Board
Independent Chairman of the Board
100.84K
+1040.00%
Mr. James C. (Jim) Momtazee
Mr. James C. (Jim) Momtazee
Independent Director
Independent Director
92.62K
+487.00%
収益内訳
FY2025Q1
事業別USD
会社名
収益
比率
VTAMA
55.13M
0.00%
地域別USD
会社名
収益
比率
United States
55.13M
0.00%
事業別
地域別
事業別USD
会社名
収益
比率
VTAMA
55.13M
0.00%
株主
更新時刻: Sat, Jan 31
更新時刻: Sat, Jan 31
株主統計
種類
株主統計
株主統計
比率
Dexcel Pharma Technologies, Ltd.
14.79%
Fidelity Management & Research Company LLC
8.73%
Ramaswamy (Vivek)
6.77%
The Vanguard Group, Inc.
6.03%
Morgan Stanley Investment Management Inc. (US)
5.85%
他の
57.83%
株主統計
株主統計
比率
Dexcel Pharma Technologies, Ltd.
14.79%
Fidelity Management & Research Company LLC
8.73%
Ramaswamy (Vivek)
6.77%
The Vanguard Group, Inc.
6.03%
Morgan Stanley Investment Management Inc. (US)
5.85%
他の
57.83%
種類
株主統計
比率
Investment Advisor
31.05%
Investment Advisor/Hedge Fund
20.09%
Hedge Fund
15.22%
Corporation
14.79%
Individual Investor
10.61%
Private Equity
9.04%
Research Firm
1.64%
Pension Fund
0.51%
Venture Capital
0.46%
機関投資家保有株
更新時刻: Thu, Jan 1
更新時刻: Thu, Jan 1
報告期間
機関投資家数
保有株式数
比率
変動額
2025Q4
723
545.88M
78.49%
-26.29M
2025Q3
690
526.70M
77.13%
-109.19M
2025Q2
673
776.63M
112.42%
-147.35M
2025Q1
676
776.88M
113.63%
-136.03M
2024Q4
645
780.70M
109.07%
-147.12M
2024Q3
601
789.51M
107.30%
-83.47M
2024Q2
564
721.13M
95.89%
-110.95M
2024Q1
518
776.24M
96.43%
-47.46M
2023Q4
449
787.20M
97.95%
-13.44M
2023Q3
421
794.31M
100.15%
+12.61M
詳細を見る
株主動向
会社名
保有株式数
比率
変動額
変動率
日付
Dexcel Pharma Technologies, Ltd.
102.85M
14.79%
--
--
Jul 01, 2025
Fidelity Management & Research Company LLC
60.73M
8.73%
+5.24M
+9.44%
Sep 30, 2025
Ramaswamy (Vivek)
47.07M
6.77%
-1.00
-0.00%
Dec 15, 2025
The Vanguard Group, Inc.
38.72M
5.57%
-521.41K
-1.33%
Sep 30, 2025
Morgan Stanley Investment Management Inc. (US)
40.65M
5.85%
+7.28M
+21.82%
Sep 30, 2025
SB Investment Advisers (UK) Limited
40.32M
5.8%
-19.64M
-32.76%
Sep 30, 2025
BlackRock Institutional Trust Company, N.A.
35.76M
5.14%
+233.57K
+0.66%
Sep 30, 2025
QVT Financial LP
28.08M
4.04%
-1.30M
-4.42%
Nov 19, 2025
Viking Global Investors LP
23.59M
3.39%
-10.64M
-31.09%
Sep 30, 2025
Rubric Capital Management LP
20.00M
2.88%
-370.34K
-1.82%
Sep 30, 2025
詳細を見る
関連ETF
更新時刻: Sat, Dec 6
更新時刻: Sat, Dec 6
銘柄名
比率
Invesco S&P MidCap 400 Pure Growth ETF
3.56%
Adaptiv Select ETF
2.91%
Virtus LifeSci Biotech Products ETF
2.79%
State Street SPDR S&P Biotech ETF
2.67%
WisdomTree US Value Fund
2.3%
ProShares Ultra Nasdaq Biotechnology
1.73%
Goldman Sachs Future Health Care Equity ETF
1.73%
Direxion Daily S&P Biotech Bull 3X Shares
1.41%
Invesco Nasdaq Biotechnology ETF
1.33%
WisdomTree BioRevolution Fund
1.3%
詳細を見る
Invesco S&P MidCap 400 Pure Growth ETF
比率3.56%
Adaptiv Select ETF
比率2.91%
Virtus LifeSci Biotech Products ETF
比率2.79%
State Street SPDR S&P Biotech ETF
比率2.67%
WisdomTree US Value Fund
比率2.3%
ProShares Ultra Nasdaq Biotechnology
比率1.73%
Goldman Sachs Future Health Care Equity ETF
比率1.73%
Direxion Daily S&P Biotech Bull 3X Shares
比率1.41%
Invesco Nasdaq Biotechnology ETF
比率1.33%
WisdomTree BioRevolution Fund
比率1.3%
配当金
過去5年間の配当金総支払額は
0.00
米ドルである。
日付
配当金
権利確定日
支払日
配当落ち日
データなし
株式分割
日付
配当落ち日
種類
比率
データなし
日付
配当落ち日
種類
比率
データなし
